Following several cases of overdose among teenagers in Belgium, linked to a challenge circulating on social media, the FAMHP reminds everyone that excessive consumption of paracetamol can have serious effects on health.

In 2025, the FAMHP introduced a new web form for questions on variations and renewals. This form should make it easier and more efficient to submit your questions. Please let us know what you think so we can continue to improve it.

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine VTx-002 for the treatment of Amyotrophic Lateral Sclerosis (ALS). The public consultation will take place from February 9th to March 11th, 2026.

Oral methotrexate can cause serious side effects in the event of overdose. Despite the measures put in place, cases of accidental overdose continue to be reported. Most cases result from taking the medicine too often compared to the prescription. For the treatment of inflammatory diseases, oral methotrexate should only be taken once a week, always on the same day.

Medication errors are a major public health problem, particularly among the elderly. Complex treatments, polypharmacy and age-related changes increase the risks. Better prevention and appropriate support are essential to ensure that medicines are used safely and effectively.

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine SGT-003 for the treatment of Duchenne Muscular Dystrophy. The public consultation will take place from 28 January to 27 February 2026.

On 10 March 2026, the Federal Agency for Medicines and Health Products is organising a study day on in-house developed medical software for healthcare institutions. For this event, the FAMHP receives support from both the FPS Public Health, Food Chain Safety and Environment and the National Institute for Health and Disability Insurance

As part of the JAMS 2.0 project, 30 joint inspections of medical device manufacturers were conducted within the European Union in 2024 and 2025. These inspections, coordinated by the FAMHP, aim to strengthen market surveillance at EU level and harmonise the operation of inspections.